The use of 2D fingerprint methods to support the assessment of structural similarity in orphan drug legislation
In the European Union, medicines are authorised for some rare disease only if they are judged to be dissimilar to authorised orphan drugs for that disease. This paper describes the use of 2D fingerprints to show the extent of the relationship between computed levels of structural similarity for pairs of molecules and expert judgments of the similarities of those pairs. The resulting relationship can be used to provide input to the assessment of new active compounds for which orphan drug authorisation is being sought.
fingerprint similarity drug registration european medicines agency molecular similarity ophan drug